Loading...
Market
What will be HilleVax's next strategic move by the end of 2024?
2
Resolution / Starting Odds
New clinical trial for different vaccine • 25%
Partnership with another biotech company • 25%
Company restructuring or layoffs • 25%
Other • 25%
Official press releases from HilleVax or industry news
Story
HilleVax Shares Plunge 88.6% to $1.60 After Norovirus Vaccine Fails in Mid-Stage Trial
Jul 8, 2024, 01:50 PM
HilleVax reported that its NEST-IN1 Phase 2b clinical study of HIL-214 in infants did not meet its primary or secondary efficacy endpoints. As a result, the company will discontinue further development of HIL-214 in infants. Following this announcement, HilleVax's stock plummeted, dropping 88.6% to $1.60 in premarket trade, with an 86.3% decline premarket. The failed trial aimed to prevent gastroenteritis caused by norovirus, specifically acute gastroenteritis. The significant decline in stock value reflects investor disappointment in the biotech company's sole clinical candidate's failure.
View original story
Similar markets
Acquisition of another company • 25%
Launch of a new drug • 25%
Restructuring or cost-cutting measures • 25%
Other strategic move • 25%
Google Ventures • 25%
Sequoia Capital • 25%
SoftBank • 25%
Other • 25%
AI-powered document search tool • 25%
AI-driven data analytics platform • 25%
AI-based customer service solution • 25%
Other • 25%
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%
New acquisition • 25%
New partnership • 25%
New product launch • 25%
No major moves • 25%
Enhanced drone technology • 25%
AI software for military • 25%
Cyber defense systems • 25%
Other • 25%
Launch a new drug • 25%
Enter a new partnership • 25%
Expand into new markets • 25%
No major changes • 25%
Yes • 50%
No • 50%
New Acquisition Target • 25%
Restructuring Plan • 25%
Partnership with Another Company • 25%
No Major Change • 25%
Yes • 50%
No • 50%
